TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Van Gogh-extension Trial, a Multicenter, International, Randomized, Double-blind, Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous SR34006 With Placebo in the Long-term Prevention of Symptomatic Venous Thromboembolism in Patients With Symptomatic Pulmonary Embolism or Deep-vein Thrombosis Who Completed 6 Months of Treatment With Vitamin K Antagonist or SR34006
Brief Summary: Patients diagnosed with pulmonary embolism (blood clot in the lung) or deep vein thrombosis (blood clot in a leg vein) are at risk for these blood clots to reoccur. Anticoagulant (blood-thinning) drugs are normally given immediately after the clot is discovered and are continued for a period of 3 or 6 months during which time the risk for recurrence is highest. Research has shown that when oral anticoagulants are used appropriately during this period, patients are less at risk for a recurrent blood clot and this risk reduction outweighs the potential for bleeding to occur.

In this study, patients who had a blood clot in the lung or in a leg vein and completed 6 months of treatment with daily oral vitamin K antagonists (acenocoumarol or warfarin) or once-weekly injections of SR34006 (a new anticoagulant drug) will receive an additional 6 months of once-weekly SR34006 injections or injections of a solution containing no drug (placebo). This trial will evaluate whether patients treated for an additional 6 months with SR34006 have fewer recurrences of blood clots when compared to patients treated with placebo.

Assignment to either SR34006 or placebo will be purely by chance. Neither the patients nor their doctors will know which treatment is being given.


Options:
A: Arm Label: Fondaparinux; Type: EXPERIMENTAL; Interventions: Drug: Fondaparinux sodium | Arm Label: unfractionated heparin; Type: OTHER; Interventions: Drug: unfractionated heparin (UFH) | Intervention Type: DRUG; Name: Fondaparinux sodium; Assigned to Arm(s): Fondaparinux | Intervention Type: DRUG; Name: unfractionated heparin (UFH); Assigned to Arm(s): unfractionated heparin
B: Intervention Type: DRUG; Name: SR34006 (idraparinux sodium) Injection; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: SR34006; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: (LMW)heparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Warfarin VKA; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Acenocoumarol VKA; Assigned to Arm(s): N/A
D: Arm Label: Fondaparinux; Type: EXPERIMENTAL; Interventions: Drug: Fondaparinux sodium | Arm Label: unfractionated heparin; Type: OTHER; Interventions: Drug: unfractionated heparin (UFH) | Intervention Type: DRUG; Name: Fondaparinux sodium; Assigned to Arm(s): Fondaparinux | Intervention Type: DRUG; Name: unfractionated heparin (UFH); Assigned to Arm(s): unfractionated heparin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Van Gogh-extension Trial, a Multicenter, International, Randomized, Double-blind, Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous SR34006 With Placebo in the Long-term Prevention of Symptomatic Venous Thromboembolism in Patients With Symptomatic Pulmonary Embolism or Deep-vein Thrombosis Who Completed 6 Months of Treatment With Vitamin K Antagonist or SR34006
Brief Summary: Patients diagnosed with pulmonary embolism (blood clot in the lung) or deep vein thrombosis (blood clot in a leg vein) are at risk for these blood clots to reoccur. Anticoagulant (blood-thinning) drugs are normally given immediately after the clot is discovered and are continued for a period of 3 or 6 months during which time the risk for recurrence is highest. Research has shown that when oral anticoagulants are used appropriately during this period, patients are less at risk for a recurrent blood clot and this risk reduction outweighs the potential for bleeding to occur.

In this study, patients who had a blood clot in the lung or in a leg vein and completed 6 months of treatment with daily oral vitamin K antagonists (acenocoumarol or warfarin) or once-weekly injections of SR34006 (a new anticoagulant drug) will receive an additional 6 months of once-weekly SR34006 injections or injections of a solution containing no drug (placebo). This trial will evaluate whether patients treated for an additional 6 months with SR34006 have fewer recurrences of blood clots when compared to patients treated with placebo.

Assignment to either SR34006 or placebo will be purely by chance. Neither the patients nor their doctors will know which treatment is being given.


Options:
A: Arm Label: Dabigatran; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran | Arm Label: Warfarin (INR of 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Dabigatran | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR of 2.0-3.0)
B: Intervention Type: DRUG; Name: SR34006 (idraparinux sodium) Injection; Assigned to Arm(s): N/A
C: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin overlapping with and followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin overlapping with and followed by VKA; Assigned to Arm(s): Enoxaparin/VKA
D: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin followed by VKA; Assigned to Arm(s): Enoxaparin/VKA

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Protocol 156-03-236: Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized With Worsening Congestive Heart Failure
Brief Summary: The purpose of this study is to compare the effectiveness of tolvaptan or placebo in adults with worsening congestive heart failure (CHF).


Options:
A: Arm Label: Active arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ivabradine | Arm Label: Placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ivabradine | Intervention Type: DRUG; Name: Ivabradine; Assigned to Arm(s): Active arm, Placebo arm
B: Intervention Type: DRUG; Name: Tolvaptan; Assigned to Arm(s): N/A
C: Arm Label: Ivabradine; Type: EXPERIMENTAL; Interventions: Drug: Ivabradine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ivabradine; Assigned to Arm(s): Ivabradine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Eplerenone arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eplerenone | Intervention Type: DRUG; Name: Eplerenone; Assigned to Arm(s): Eplerenone arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Protocol 156-03-236: Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized With Worsening Congestive Heart Failure
Brief Summary: The purpose of this study is to compare the effectiveness of tolvaptan or placebo in adults with worsening congestive heart failure (CHF).


Options:
A: Intervention Type: DRUG; Name: Tolvaptan; Assigned to Arm(s): N/A
B: Arm Label: Lixivaptan; Type: EXPERIMENTAL; Interventions: Drug: Lixivaptan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lixivaptan; Assigned to Arm(s): Lixivaptan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: satavaptan (SR121463B); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: SR121463B; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients With Idiopathic Pulmonary Fibrosis, Open Label Extension
Brief Summary: Endothelin-1 (ET-1) is expressed in a variety of pulmonary pathological conditions including pulmonary vascular disease and pulmonary fibrosis.

Bosentan (an oral dual ET-1 receptor antagonist) could delay the progression of idiopathic pulmonary fibrosis (IPF), a condition for which no established treatment is available.

The present trial investigates a possible use of bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) WHO class III and IV, to a new category of patients suffering from IPF.

It was decided to offer Open Label treatment (bosentan) for patients willing to continue in the BUILD 1 study.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: bosentan | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bosentan | Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: bosentan | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Bosentan administration; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients With Idiopathic Pulmonary Fibrosis, Open Label Extension
Brief Summary: Endothelin-1 (ET-1) is expressed in a variety of pulmonary pathological conditions including pulmonary vascular disease and pulmonary fibrosis.

Bosentan (an oral dual ET-1 receptor antagonist) could delay the progression of idiopathic pulmonary fibrosis (IPF), a condition for which no established treatment is available.

The present trial investigates a possible use of bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) WHO class III and IV, to a new category of patients suffering from IPF.

It was decided to offer Open Label treatment (bosentan) for patients willing to continue in the BUILD 1 study.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: bosentan | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Bosentan; Type: EXPERIMENTAL; Interventions: Drug: Bosentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Bosentan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Bosentan for 16 weeks; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bosentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Bosentan for 16 weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Bosentan for 16 weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Part 1; Type: EXPERIMENTAL; Interventions: Drug: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose, Drug: Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently) | Arm Label: Part 2; Type: EXPERIMENTAL; Interventions: Drug: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose, Drug: Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently) | Arm Label: Part 3; Type: EXPERIMENTAL; Interventions: Drug: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose | Intervention Type: DRUG; Name: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose; Assigned to Arm(s): Part 1, Part 2, Part 3 | Intervention Type: DRUG; Name: Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently); Assigned to Arm(s): Part 1, Part 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Systemic Lupus Erythematosus (SLE)
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of 3 different doses of belimumab, administered in addition to standard therapy, in patients with active SLE disease.


Options:
A: Arm Label: EXERCISE GROUP; Type: EXPERIMENTAL; Interventions: Behavioral: HAND EXERCISE | Arm Label: CONTROL GROUP; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: HAND EXERCISE; Assigned to Arm(s): EXERCISE GROUP
B: Arm Label: Supervised HIIT; Type: EXPERIMENTAL; Interventions: Behavioral: Effective endurance 4x4 training - Supervised | Arm Label: APP HIIT; Type: EXPERIMENTAL; Interventions: Device: Effective endurance 4x4 training - APP | Intervention Type: BEHAVIORAL; Name: Effective endurance 4x4 training - Supervised; Assigned to Arm(s): Supervised HIIT | Intervention Type: DEVICE; Name: Effective endurance 4x4 training - APP; Assigned to Arm(s): APP HIIT
C: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Healthy control; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training | Intervention Type: BEHAVIORAL; Name: Exercise training; Assigned to Arm(s): Exercise, Healthy control
D: Arm Label: Placebo plus SOC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Belimumab 1 mg/kg plus SOC; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 1 mg/kg | Arm Label: Belimumab 4 mg/kg plus SOC; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 4 mg/kg | Arm Label: Belimumab 10 mg/kg plus SOC; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 10 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus SOC | Intervention Type: DRUG; Name: Belimumab 1 mg/kg; Assigned to Arm(s): Belimumab 1 mg/kg plus SOC | Intervention Type: DRUG; Name: Belimumab 4 mg/kg; Assigned to Arm(s): Belimumab 4 mg/kg plus SOC | Intervention Type: DRUG; Name: Belimumab 10 mg/kg; Assigned to Arm(s): Belimumab 10 mg/kg plus SOC

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Youth Support Team Intervention for Suicidal Adolescents
Brief Summary: This study will attempt to improve treatment adherence and reduce suicide risk among adolescents who are at risk for attempting suicide.


Options:
A: Arm Label: SAFE VET; Type: N/A; Interventions: Behavioral: SAFE VET | Arm Label: E-CARE; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SAFE VET; Assigned to Arm(s): SAFE VET
B: Arm Label: Control (volitional help sheet); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Volitional help sheet | Arm Label: Intervention (volitional help sheet); Type: EXPERIMENTAL; Interventions: Behavioral: Volitional help sheet | Intervention Type: BEHAVIORAL; Name: Volitional help sheet; Assigned to Arm(s): Control (volitional help sheet) | Intervention Type: BEHAVIORAL; Name: Volitional help sheet; Assigned to Arm(s): Intervention (volitional help sheet)
C: Arm Label: Youth-Nominated Support Team; Type: EXPERIMENTAL; Interventions: Behavioral: Youth-Nominated Support Team | Arm Label: Enhanced Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Youth-Nominated Support Team; Assigned to Arm(s): Youth-Nominated Support Team
D: Arm Label: Commitment; Type: EXPERIMENTAL; Interventions: Behavioral: DBT Skills Training | Arm Label: Psychoeducation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DBT Skills Training | Intervention Type: BEHAVIORAL; Name: DBT Skills Training; Assigned to Arm(s): Commitment, Psychoeducation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Youth Support Team Intervention for Suicidal Adolescents
Brief Summary: This study will attempt to improve treatment adherence and reduce suicide risk among adolescents who are at risk for attempting suicide.


Options:
A: Arm Label: Youth-Nominated Support Team; Type: EXPERIMENTAL; Interventions: Behavioral: Youth-Nominated Support Team | Arm Label: Enhanced Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Youth-Nominated Support Team; Assigned to Arm(s): Youth-Nominated Support Team
B: Arm Label: Family-Enhanced Non-directive Supportive Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Family-Enhanced Non-directive Supportive Therapy | Arm Label: Attachment-Based Family Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Attachment-Based Family Therapy | Intervention Type: BEHAVIORAL; Name: Attachment-Based Family Therapy; Assigned to Arm(s): Attachment-Based Family Therapy | Intervention Type: BEHAVIORAL; Name: Family-Enhanced Non-directive Supportive Therapy; Assigned to Arm(s): Family-Enhanced Non-directive Supportive Therapy
C: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Psychoeducational intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Psychoeducational intervention; Assigned to Arm(s): Intervention group
D: Arm Label: Intensive Outpatient CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive Outpatient CBT | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Care | Intervention Type: BEHAVIORAL; Name: Intensive Outpatient CBT; Assigned to Arm(s): Intensive Outpatient CBT | Intervention Type: BEHAVIORAL; Name: Standard Care; Assigned to Arm(s): Standard Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Youth Support Team Intervention for Suicidal Adolescents
Brief Summary: This study will attempt to improve treatment adherence and reduce suicide risk among adolescents who are at risk for attempting suicide.


Options:
A: Arm Label: Escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): Escitalopram | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical behavioral therapy for adolescents (DBT-A) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Dialectical behavioral therapy for adolescents (DBT-A); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Attachment-Based Family Therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Usual Care | Intervention Type: BEHAVIORAL; Name: Attachment-Based Family Therapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Enhanced Usual Care; Assigned to Arm(s): 2
D: Arm Label: Youth-Nominated Support Team; Type: EXPERIMENTAL; Interventions: Behavioral: Youth-Nominated Support Team | Arm Label: Enhanced Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Youth-Nominated Support Team; Assigned to Arm(s): Youth-Nominated Support Team

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Post-Stroke Depression - Treatment Strategy
Brief Summary: This study will evaluate the effectiveness of both drug and non-drug treatments in preventing depression after a stroke.


Options:
A: Arm Label: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug); Type: ACTIVE_COMPARATOR; Interventions: Drug: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo | Arm Label: Placebo Tablet; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo; Assigned to Arm(s): Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Tablet
B: Arm Label: ICU Diaries; Type: EXPERIMENTAL; Interventions: Behavioral: ICU Diary | Arm Label: Psychoeducation; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducation | Arm Label: ICU Diary plus Psychoeducation; Type: EXPERIMENTAL; Interventions: Behavioral: ICU Diary, Behavioral: Psychoeducation | Arm Label: Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ICU Diary; Assigned to Arm(s): ICU Diaries, ICU Diary plus Psychoeducation | Intervention Type: BEHAVIORAL; Name: Psychoeducation; Assigned to Arm(s): ICU Diary plus Psychoeducation, Psychoeducation
C: Arm Label: BA-LVR; Type: EXPERIMENTAL; Interventions: Behavioral: BA-LVR | Arm Label: ST-LVR; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: ST-LVR | Intervention Type: BEHAVIORAL; Name: BA-LVR; Assigned to Arm(s): BA-LVR | Intervention Type: BEHAVIORAL; Name: ST-LVR; Assigned to Arm(s): ST-LVR
D: Arm Label: 1 Problem Solving Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving Therapy | Arm Label: 2. Escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: 3 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy; Assigned to Arm(s): 1 Problem Solving Therapy | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): 2. Escitalopram | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 3 Placebo

Answer: D